Persistence at 2 years was 52.961 period a cohort of 112 psoriatic patients (57% men) were evaluated: 37 patients translate any time-savings to cost savings. for each stage during 113 patients' implantation procedure. A literature review ness ratios, that have been obtained when simulating various effect and pric- cal need and the expected unprecedented efficacy of next generation AVDs will ness therapies, that have been obtained when simulating various effect and price- scenarios, will be regarded as acceptable from a German health care payer perspective.

OBJECTIVES: Intraoperative threshold measurement is a part of the cochlear implantation procedure and in the current setting conducted by the clinicians with a standard setup. The newly released CR220 Intraoperative Remote Assistant is a handheld device and can also be used by someone already in the operating theater. The aim of this study was to compare the time-savings to the new CR220 and standard setup and to investigate from the clinician's perspective any cost-savings created as a result of time-savings with the new device. METHODS: Stages of the measurement protocol are identified and the time is measured for each stage during 113 patients' implantation procedure. A literature review was conducted to identify the reimbursement level of this process in order to translate any time-savings to cost savings. RESULTS: When the clinician's de- els to the OT, the mean time spent per procedure with CR220 is 8.4% less than the computer set-up (163.7 minutes vs 149.9 minutes). If the measurement is conducted by someone already in the OR, the measurement time is reduced by 95.5% with the CR220 (163.7 minutes vs 7.3 minutes). Literature review revealed that the fee for measurement as $18.99-22.57 per 15 minutes in the US setting and in most of the other settings this procedure is not reimbursed separately but covered under cochlear implantation. CONCLUSIONS: The analysis showed that considerable time is spent for the clinician to travel to OT and waiting in the OT. This "unproductive" time is not only wasteful, but also means the clinician is not available in the clinic seeing patients where their expert skills are of most value. Moreover, the clinician is either underpaid or is not valued for their expertise and time demanding process. The new CR220 gives clinics the opportunity to allocate their limited resources efficiently.

MATERIALS AND METHODS: A total of 1,006 naïve glaucoma patients were enrolled in the study. Of the total, 34% showed to be non-adherent to their glaucoma therapy and 7.5% had the experi- ence of medication discontinuation. All patients were categorized into 3 groups according to disease duration: A: ≤ 1 year (n=24), B: 1-2 years (n=415,39.5%), and C: > 2 years (n=35, 3%). The patients of group A with the disease duration ≤ 1 year were likely to be non-adherent to glaucoma therapy compared to those with longer disease duration. (A: 84.9% vs. B: 86% vs. C: 100%, p<0.001). The study was found in group B with the disease durations between 1 and 2 years. (A: 6.7% vs. B: 8.9% vs. C: 5.7%, p< 0.380) CONCLUSIONS: The study results highlight more attention should be paid to the patients who newly started glaucoma therapy because in the patients with less than 2 years of disease duration the adherence was low and the discontinuation rate was high.

OBJECTIVES: To compare a newly developed condition-specific utility index (CSUI), the Pressure Ulcer Quality of Life Utility Index (PUQul-UI) with generic and directly elicited utilities. METHODS: A total of 426 patients were recruited at three glaucoma clinics (n=100) in England with pressure ulcers (PUs) along with the EQ-SD and own health TTO. The discriminatory power of the utility measures was assessed across PU grade and health and PU severity ratings. Multivariate regression was conducted to explore determinants of utility values. RESULTS: The mean sample age was 77.2 years (range 22.7-101.7), 49% were female and 50% wheelchair users. Mean (SD) utility for superficial PUs (grades 1-2) were 0.72 (0.17), 0.70 (0.05) and 0.24 (0.16) and for severe PUs (grades 3-4) 0.06 (0.35) and 0.65 (0.35) and for the PUQul-UI, TTO and EQ-SD, respectively. Mean (SD) utility by self-reported PU severity was: [Mild] 0.78 (0.16), 0.66 (0.35), 0.29 (0.36); [Moderate] 0.72 (0.17), 0.63 (0.38), 0.25 (0.34); [Severe] 0.58 (0.19), 0.70 (0.35), 0.04 (0.46) for the PUQul-UI, TTO and EQ-SD, respectively. Regression analyses indicated both EQ-SD and PUQul-UI values were explained by perceived severity and general health ratings but not demographics or PU grade. Duration and body part affected were additional significant explanatory factors of the EQ-SD while wheelchair use approached significance. CONCLUSIONS: Values were much lower for the EQ-SD than the other assessments which may be partly explained by the range in EQ-SD and partly due to background mobility issues being captured. This good discriminatory power and it is recommended for use in trials of PU interventions. The utilities presented here will be useful for decision-analytic models that incorporate PU impact. Probabilistic sensitivity analysis with including the PUQul-UI will likely generate lower levels of uncertainty than the EQ-SD due to the smaller SDs for health states.

OBJECTIVES: To estimate utility data for patient symptom severity in chronic spontaneous urticaria. cohesive outcomes research. 3) A parsimonious model was selected using the approach of backwards elimination; all predictors that were considered through visual comparisons and interaction terms.

RESULTS: There was a consistent improvement in EQ-SD utilities as severity of urticaria improved. Mean utility differences of 0.12 ranged from 12% improvement in patients with severe urticaria to 0.897 in patients who were urticaria-free. Sensitivity analysis confirmed the robustness of results.

CONCLUSIONS: The results suggest that EQ-SD utility score increased with decreasing severity of urticaria. EQ-SD utility score allows the comparison of HRQoL across different diseases by calculating QALYs in economic models.

SENSORY SYSTEMS DISORDERS – Patient-Reported Outcomes & Patient Preference Studies

PSS37

Drug survival rates and cost of biological agents for the treatment of moderate to severe psoriasis in the Balearic Islands (Spain)

Vinent J
Hospital de Esparos, Palma de Mallorca, Spain

OBJECTIVES: There are few studies combining dose regimen in routine clinical practice, drug survival rates and costs of biological agents for the treatment of naive patients with moderate-to-severe psoriasis in the clinical practice. To assess the dose regimen in routine clinical practice, drug survival rate (perseverance rate) and efficacy (cost per persistence) for etanercept (ETN), adalimumab (ADA) and ustekinumab (UST) in a real practice clinical setting. METHODS: A retrospective study on psoriasis patients aged ≥18 years, naive to a biological agent and a mini- mum of 6 months of treatment was performed in 5 public health system hospitals in the Balearic Islands (Spain) for the period from January 1st 2010 to December 31st 2013. The recorded variables were: sex, weight, age, indication (psoriasis or psoriatic arthritis), discontinuation reason and pharmacy dispensation records. Costs were based on the average wholesale price, estimating annual cost according to the first treatment received. Persistence rates were reckoned taking into account the current total days of therapy comparing posology with pharmacy supplied dose, and were estimated using the method of Kaplan-Meier. RESULTS: During the study period a cohort of 112 psoriatic patients (57% men) were evaluated: 37 patients with ADA (81 kg, 51 years, 27, mean weight, mean age, and prevalence of psoriatic arthritis respectively), 34 with ETN (82 kg, 52 years, 25%) and 41 with UST (76 kg, 43 years, 19%). The persistence rate at 2 years was, 48%, 62% and 81% and the cost per persistence at 2 years was $92.96/1, 40, 160 € and $30,657 /€ (for ADA, ETN and UST respectively). CONCLUSIONS: UST showed better overall drug survival compared to ETN and ADA. UST has been the most efficient alternative for the treatment of naive patients and has shown the least budget-impact per persistent-patient at 2 years analysis.

PSS38

Medication adherence and discontinuation predicted by disease severity in glaucoma patients: findings from a cross-sectional study in Korea

Park EH, Cha HJ
Seoul National University College of Medicine, Seoul, South Korea, 2Pfizer Pharmaceuticals Korea Ltd., Seoul, South Korea

OBJECTIVES: Although several studies reported patients with chronic disease were adherent in clinical trials, various possible effect and pricing scenarios have been simulated. RESULTS: Applying the base case settings resulted in incremental costs of $107,925, in 2.03 incremental quality-adjusted life years (QALY’s) and in a cost-effectiveness ratio of $52,165 per QALY gained. Probabilistic, deterministic sensitivity analyses as well as scenario analyses for the effect size and the AVD costs were performed in order to investigate the robustness of results. In these analyses a strong variation of the cost-effectiveness results was observed ranging from €23,512 (best case) to €176,958 (worst case) per QALY gained. CONCLUSIONS: The innovative nature, the high unmet medical need and the expected unprecedented efficacy of next generation AVDs will likely highly lead to the case that even relatively high incremental cost effectiveness ratios, that have been obtained when simulating various effect and pricing scenarios, will be regarded as acceptable from a German health care payer perspective.